Robert Lutz
Company: Iksuda Therapeutics
Job title: Chief Scientific Officer
Seminars:
Chair’s Closing Remarks 3:00 pm
day: Scientific Program Day Two
Chairs Opening Remarks 8:25 am
day: Scientific Program Day Two
Evaluating Emerging ADC Designs to Understand Their Impact on Safety Profiles – Where Are We Headed? 11:00 am
Reviewing new ADC designs and how they may lead to improved safety profiles such as reduced neutropenia and GI toxicities Discussing the challenges of preclinical to clinical translation of safety profiles – how can we design ADCs to be safer based on preclinical evaluation? Exploring how ADC design innovations will support future differentiation and improve…Read more
day: Scientific Program Day Two